47 results about "CD64" patented technology

The invention discloses a kit and method for detecting leukemia and lymphoma based on full-spectrum flow cytometry, the kit comprises 25 antibodies, the antibodies are specifically bound with fluorescein respectively, and leukemia and lymphoma are detected through full-spectrum flow cytometry; the 25 kinds of antibodies comprise HLA-DR (human leukocyte antigen-DR), CD38, CD7, CD34, Lambda, CD19, CD64, CD14, CD5, CD123, CD16, CD20, Kappa, CD117, CD13, CD45, CD11b, CD2, CD10, CD8, CD15, CD4, CD3, CD56 and CD33. The kit comprehensively covers development stages of various lines of bone marrow cells, and common abnormal expressions of various leukemia, myelodysplastic syndromes and lymphoma, and can preliminarily screen various leukemia and lymphoma.

The invention discloses a reagent for rapidly distinguishing bacterial and virus infection and application, belongs to the field of molecular biology, relates to medical and biotechnology, and aims to solve the problem that a traditional method cannot clearly distinguish bacterial infection from virus infection. The reagent comprises five antibodies marked with different fluorescence. The five antibodies are all mouse anti-human or rabbit anti-human antibodies, and targets corresponding to the five antibodies are respectively CD45, CD14, CD64, CD169 and HLA-DR (human leukocyte antigen-DR). The tail end of the antibody is connected with different fluorescein through chemical reaction; fluorescence labeling is performed on neutrophils, mononuclear cells and lymphocytes in peripheral blood through an antibody combination of CD molecules, and corresponding infection indexes are calculated through a flow cytometry method, so that the infection type (bacterial / virus infection) of a patient is quickly distinguished and judged.

The invention relates to an antibody composition, a kit and a system for rapidly screening acute promyelocytic leukemia. The antibody composition comprises a first group of antibodies, a second group of antibodies and a third group of antibodies, the first group of antibodies comprises a CD71 antibody, a CD33 antibody, a CD117 antibody, a CD34 antibody, an HLA-DR antibody, a CD19 antibody, a CD10 antibody, a CD7 antibody and a CD45 antibody; the second group of antibodies comprises a CD38 antibody, a CD56 antibody, a CD16 antibody, a CD34 antibody, a CD13 antibody, a CD11b antibody, a CD64 antibody, a CD15 antibody and a CD45 antibody; the third group of antibodies comprises a CD9 antibody, an MPO antibody, a CD117 antibody and a CD45 antibody; and each antibody is a monoclonal antibody marked with a detection marker. The antibody composition comprises a CD117 + CD33 + region as a main target cell population, and covers three groups of antibodies for identifying acute promyelocytic leukemia, such as CD33, CD34, CD64, CD13, CD9 and MPO, the acute promyelocytic leukemia can be rapidly, simply and conveniently detected by adopting the antibody composition, the detection sensitivity is high, the specificity is high, the accuracy rate is high, and the antibody composition can be widely applied to detection of acute promyelocytic leukemia. The acute promyelocytic leukemia patient can be accurately and quickly identified, and early diagnosis and early treatment are realized.

A method of treating male hypogonadism in a subject in need thereof includes administering to the subject testicular organoids generated from isolated male progenitor cells. The method can be used to slow or halt the progression of age-related diseases, and increase healthspan and longevity, in hypogonadal males. The method can be used with subjects that have not or are not receiving testosterone replacement therapy. The method does not require that the subject is pre-treated with CG. The testicular organoid includes cells expressing GFRA1, VEGF, VEGFR2, PDGF-Rα, Cyp11A1, 3β-HSD, 17β-HSD, LHCGR, α-SMA, CD11b, MHC CII, CD64, CD95, Sox9, AR, inhibin β-B, and FSHR.

The invention discloses an antibody composition for detecting mother cell plasma cell-like dendritic cells. The antibody composition comprises a first group of antibodies, a second group of antibodies, a third group of antibodies and a fourth group of antibodies, the first group of antibodies comprises a CD36 antibody, a CD4 antibody, a CD14 antibody, a CD56 antibody, a CD5 antibody, a CD3 antibody, a CD8 antibody, a CD2 antibody, a CD7 antibody and a CD45 antibody; the second group of antibodies comprises an HLA-DR (Human Leukocyte Antigen-DR) antibody, a CD33 antibody, a CD34 antibody, a CD56 antibody, a CD117 antibody, a CD123 antibody, a CD19 antibody, a CD38 antibody and a CD45 antibody; the third group of antibodies comprises a CD303 antibody, a CD304 antibody, a CD41 antibody, a CD56 antibody, a CD13 antibody, a CD85j antibody, a CD64 antibody, a CD15 antibody and a CD45 antibody; and the fourth group of antibodies comprises TdT, MPO, CD56, cCD3, CD10, cCD22 and CD45 antibodies. The antibody composition can be used for accurately detecting tumor abnormal BPDCN cells.

The disclosure describes T cells that express chimeric antigen receptors (CARs), as well as pharmaceutical compositions comprising T cells and methods of making and using such T cells. Particularly, this disclosure describes T cells expressing a CAR that binds to CD64, and methods of use in treating acute myeloid leukemia.

Described herein are novel vaccine compositions and methods for use thereof in inducing an immune response in a subject especially aged subjects. Specifically exemplified are vaccine compositions that include an antigen; a cyclic dinucleotide; soluble tumor necrosis factor (TNF); or a CD64 antibody or antibody fragment. Optionally, the vaccine composition comprises a TNF conjugated with a moDC targeting moiety in addition to or in place of TNF or CD64 antibody or antibody fragment, or both TNF and CD64 antibody or antibody fragment.

The invention relates to the technical field of cell culture, in particular to an NK cell in-vitro amplification method and application thereof. The invention provides a method for amplifying NK cells, which comprises the following steps: mixing the NK cells with aAPC, activating the NK cells, and culturing the activated NK cells in a culture medium to realize multiplication culture of the NK cells, the aAPC expresses human-derived CD64 protein, and the activating treatment comprises incubation treatment with the NK cells and the aAPC by using an anti-CD56 antibody. The method is simple, efficient and low in risk, a serum-free and animal-source-component-free culture system is adopted in the whole process, the amplification multiple of the NK cells can reach hundreds of thousands of times or above after the NK cells are cultured for 28 days, the purity of the NK cells can reach 95% or above, the requirements of clinical immune cell therapy are met, and the method has high clinical transformation potential.

The invention relates to the technical field of biological medicine, in particular to application of S100A9 protein to preparation of a product for predicting the recurrence risk of AML. The product is used for detecting a marker CD15, a marker CD33, a marker CD14, a marker CD15, a marker CD33, a marker CD64, a marker CD5, a marker CD14, a marker CD10, a marker CD19, a marker CD33, a marker CD34, a marker CD64, a marker CD117, a marker CD13 or a marker CD45. Therefore, the accuracy of predicting the AML recurrence risk is improved.

To provide a recombinant immunocyte, a manufacture method, and a use method.SOLUTION: A recombinant immunocyte expresses a heterogeneous IgG Fc receptor. In some embodiments, the heterogeneous IgG Fc receptor can be a chimera IgG Fc receptor. Generally, the chimera IgG Fc receptor includes an extracellular domain, a transmembrane domain and an intracellular domain. The extracellular domain generally includes an area of CD64 sufficient to be bonded to the IgG Fc region. An intracellular domain of the chimera IgG Fc receptor includes a sufficient area of the Fc receptor, which makes it possible for an immunoreceptor tyrosine-based activation motif (ITAM) to start cell signaling when the IgG Fc region binds to the extracellular domain.SELECTED DRAWING: None

The invention discloses a CD64 infection index detection kit and a method for quality control by using the kit, the kit comprises an antibody reagent, a buffer solution and a blocking agent, the antibody reagent comprises four antibodies marked by different fluorescence markers, namely CD64, CD14, CD45 and HLA-DR, and the buffer solution is PBS; the blocking agent is a mixed blocking agent composed of mouse IgG, a HAMA blocking agent and heparin sodium; the addition concentration of the mouse IgG, the HAMA blocking agent and the heparin sodium mixed blocking agent is not less than 1.34 mu g / mL and not more than 10 mu g / mL. A blocking agent is added into the kit to reduce background fluorescence of negative control lymphocytes, so that the accuracy of a detection result is improved, meanwhile, compensation microspheres, calibration microspheres and a quality control product are introduced to be used for standardized establishment and verification of a detection template, and the consistency of the detection result is improved.

The invention provides an antibody composition for detecting immature mononuclear cells and application thereof, the antibody composition for detecting the immature mononuclear cells comprises a first group of antibodies and a second group of antibodies, the first group of antibodies comprises a CD15 antibody, a CD117 antibody, a CD34 antibody, a CD33 antibody, a CD14 antibody, an HLA-DR antibody, a CD13 antibody, a CD38 antibody, a CD64 antibody, a CD19 antibody, a CD56 antibody, a CD7 antibody and a CD45 antibody; and the second group of antibodies comprise an HLA-DR antibody, a CD64 antibody, a CD33 antibody, a CD14 antibody, a CD65 antibody and a CD45 antibody. According to the present invention, the flow cytometry is adopted to detect, and the antibody composition of the first group of antibodies and the second group of antibodies is provided, such that the detection sensitivity and the specificity are improved.

The disclosure describes T cells that express chimeric antigen receptors (CARs), as well as pharmaceutical compositions comprising T cells and methods of making and using such T cells. Particularly, this disclosure describes T cells expressing a CAR that binds to CD64, and methods of use in treating acute myeloid leukemia.

The application relates to the technical field of medical detection, in particular to a kit, a method and a system for predicting bacterial infection. The application provides a kit for predicting bacterial infection, which comprises an antibody combination for specifically recognizing CD64, CD14 and CD14, and the antibodies are respectively labeled with mutually distinguishable fluorescent dyes. Meanwhile, the application provides a method for predicting bacterial infection, which comprises obtaining the counts of neutrophils, lymphocytes and monocytes in a to-be-detected sample, and the fluorescent intensities of CD64 and CD14 on the cell subgroups, and calculating four characteristic parameters IDXNLR, IDXLMR, IDXCD64 and IDXCD14; and then inputting the parameters into a pre-trained infection diagnosis model to output a risk score for judging the infection state (especially bacterial infection). The model significantly improves the accuracy and specificity of distinguishing bacterial infection from non-bacterial infection (such as viral infection or healthy state) by comprehensively integrating immune parameters in multiple dimensions.

Provided herein are compositions, systems, and methods for producing small extracellular vesicles (sEVs) that are mRNA-loaded and include CD64 on the sEV surface. Also provided are the immunogenic EVs (imsEVs) that further include a targeting ligand bound to the CD64 on the imsEV surface. The disclosure also provides fusion proteins including a CD64 amino acid sequence fused to an N peptide amino acid sequence. Also provided are nucleic acids that encode the fusion proteins, and vectors and cells that comprise the nucleic acids. Also disclosed are methods for using the imsEVs for immunotherapy, such as for the treatment of cancer in a subject.

The present invention provides compositions and methods for treating or ameliorating advanced cancers, such as drug-resistant or metastatic cancers, or killing cancer stem cells expressing an alpha v beta 3 polypeptide on its cell surface by using a human antibody or a humanized antibody, and the human antibody or humanized antibody is capable of specifically binding to an [alpha] v [beta] 3 (avb3) polypeptide expressed on the cell surface of effector cells such as macrophages, neutrophils and dendritic cells, the Fc region of which has selective affinity for human Fc [gamma] RI (CD64) but does not have selective affinity for other Fc [gamma] R. By administering these antibodies to an individual in need thereof, these human antibodies or humanized antibodies can treat, ameliorate, or slow the progression of advanced cancers or drug resistant cancers or cancers caused, initiated, or maintained by advanced cancers or drug resistant cancer cells or cancer stem cells.

The invention belongs to the technical field of immunological detection, and discloses an antibody composition for detecting early precursor acute T-cell lymphocytes, which comprises a first group of antibodies, a second group of antibodies and a third group of antibodies, the first group of antibodies comprises a CD99 antibody, a CD4 antibody, a CD34 antibody, a CD56 antibody, a CD5 antibody, a CD3 antibody, a CD8 antibody, a CD2 antibody, a CD7 antibody and a CD45 antibody; the second group of antibodies comprises an HLA-DR (Human Leukocyte Antigen-DR) antibody, a CD33 antibody, a CD34 antibody, a CD117 antibody, a CD13 antibody, a CD11b antibody, a CD7 antibody, a CD64 antibody, a CD38 antibody and a CD45 antibody; the third group of antibodies comprises a TdT antibody, an MPO antibody, a CD10 antibody, a CD1a antibody, a cCD3 antibody, a CD7 antibody, a CD19 antibody, a cCD22 antibody and a CD45 antibody; each antibody is a monoclonal antibody marked with a detection marker. The antibody composition can be used for rapidly, accurately and comprehensively detecting early-stage precursor T cell acute lymphocytes at one time.

An anti-canine CD16 polypeptide generally includes a CDR region of SEQ ID NO:5, a CDR region of SEQ ID NO:9, or a functional variant of either CDR region. An anti-canine CD64 polypeptide generally includes a CDR region of SEQ ID NO:13, a CDR region of SEQ ID NO:17, or a functional variant of either CDR region. The anti-canine CD16 polypeptide and anti-canine CD64 polypeptide may be incorporated into a therapeutic compound, a multispecific compound, a targeted imaging compound, or a capture assay device.

The invention provides an anti-human CD64 mouse monoclonal antibody as well as a product and application thereof, and relates to the technical field of antibodies. A heavy chain variable region of the anti-human CD64 antibody comprises HCDR1-HCDR3 of which the amino acid sequence is shown as SEQ ID NO.1-3, or HCDR1-HCDR3 of which the amino acid sequence has at least one amino acid difference compared with the amino acid sequence shown as SEQ ID NO.1-3; a light chain variable region of the gene has LCDR1-LCDR3 of which the amino acid sequence is shown as SEQ ID NO.1-4, or LCDR1-LCDR3 of which at least one amino acid difference exists compared with the amino acid sequence shown as SEQ ID NO.4-6. The antibody can specifically recognize the human CD64 antigen, and the expression yield of the antibody reaches the level of g / L and is far higher than the yield of the antibody prepared by traditional hybridoma cells.

The invention relates to the technical field of immunotherapy, in particular to chimeric antigen receptor macrophages of a v5 exon targeting CD44 and application of the chimeric antigen receptor macrophages. According to the chimeric antigen receptor of the v5 exon targeting CD44, the chimeric antigen receptor sequentially comprises a signal peptide, an anti-CD44v5 single-chain antibody, a hinge region, a transmembrane region and an intracellular signal region from the N end to the C end, the anti-CD44v5 single-chain antibody is encoded by a gene with a nucleotide sequence shown as SEQ ID NO.6, and the CD44v5 single-chain antibody is encoded by a gene with a nucleotide sequence shown as SEQ ID NO.6. And the intracellular signal region comprises Fc epsilon R I or CD64. The chimeric antigen receptor macrophage CAR-M expresses a chimeric antigen receptor of a v5 exon targeting CD44, has remarkable phagocytosis and killing effects on breast cancer / gastric cancer cells, is excellent in safety performance, can be used for preparing related tumor treatment drugs, and has huge social and economic benefits.

A recombinant immune cell expresses a heterologous IgG Fc receptor. In some embodiments, the heterologous IgG Fc receptor can be a chimeric IgG Fc receptor. Generally, the chimeric IgG Fc receptor includes an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain generally includes a sufficient portion of CD64 to bind to an IgG Fc region. The intracellular domain of the chimeric IgG Fc receptor includes a sufficient portion of an Fc receptor allowing immunoreceptor tyrosine-based activation motif (ITAM) to initiate cell signaling when an IgG Fc region binds to the extracellular domain.

In some embodiments, compositions and methods relating to isolated artificial antigen presenting cells (aAPCs) are disclosed, including aAPCs comprising a U937 cell modified to express one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. Further provided are lipid nanoparticles (LNPs) conjugated to one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. In some embodiments, methods of expanding tumor infiltrating lymphocytes (TILs) with aAPCs or LNPs and methods of treating cancers using TILs after expansion with aAPCs or LNPs are also disclosed.

The present invention relates to: a recombinant Fc receptor which has ADAM17 cleavage resistance by modifying an amino acid at an ADAM17 cleavage site of a CD16 polypeptide, and which can improve binding affinity with an antibody Fc region by replacing all or a part of an extracellular binding domain of CD64;

The invention provides an antibody composition for detecting AML (acute myeloid leukemia) accompanied with CBF beta MYH11. The antibody composition comprises CD2, CD34, CD117, CD64, CD14, CD33, HLA-DR (human leukocyte antigen-DR), CD15, CD11b, CD13, CD38 and CD45 antibodies. During detection, the antibody composition is divided into two types of antibody combinations according to detection targets, and then samples are respectively added for flow cytometry detection; when the proportion of original myeloid cells / nucleated cells is between 6% and 78%, the proportion of mononuclear cells / nucleated cells is greater than 22%, and the proportion of CD2 / mononuclear cells is greater than 20%, determining that the sample is AML with CBF beta MYH11. The method provided by the invention is simple and low in cost, can be used for judging whether the AML patient has CBF beta MYH11 positive or not without further molecular biological PCR (Polymerase Chain Reaction) screening, and has a great practical value.

The application discloses a nucleic acid aptamer capable of recognizing and combining with CD64 protein and application thereof. The application provides various nucleic acid aptamers and mutants thereof. The nucleic acid aptamer has high affinity, is non-immunogenic, can be chemically synthesized in vitro, has small molecular weight, can be modified and replaced at different positions, is stable in sequence, easy to preserve, convenient to label (without a secondary antibody), and the like. When the nucleic acid aptamer is used for detecting CD64 protein, the operation is simple and rapid, the affinity is high, the synthesis cost of the nucleic acid aptamer is lower than that of an antibody, the period is short, and the reproducibility is good. The application can be used in many fields such as disease diagnosis and treatment, drug screening, molecular recognition and analysis detection, and the like.

The human bone marrow (BM) microenvironment involves hematopoietic and non-hematopoietic cell subsets organized in a rather complex architecture. Tremendous efforts have been made to model it in order to analyse normal or pathological hematopoiesis and its stromal counterpart. Herein, the inventors report an original, fully-human in vitro 3D model of the BM microenvironment dedicated to study interactions taking place between mesenchymal stromal cells (MSC) and hematopoietic stem and progenitor cells (HSPC) during the hematopoietic differentiation. This fully-human artificial marrow organoid (AMO) model is highly efficient to recapitulate MSC support to myeloid differentiation and NK cell development from the most immature CD34+ HSPC to the most terminally differentiated CD15+ CD64+ polymorphonuclear neutrophils or NKG2A-KIR2D+CD57+ NK subset. Interestingly, mature NK cell's phenotype showed significant differences after AMO-based culture compared to a conventional 2D co-culture system in the expression of adhesion molecules and immune checkpoint receptors, suggesting that the 3D model is more suitable to study the BM immunosuppressive microenvironment. Thus, the present invention relates to the use of an artificial marrow organoid for generating NK cells and myeloid cells.

Provided herein are, inter alia, polypeptides and covalent complexes including the same, with multivalent binding specificity. The polypeptides include an Fc receptor portion / domain (e.g., a CD16 domain, a CD32 domain, a CD64 domain and variants thereof) with a cysteine amino acid substitution capapble of forming a disulfide linkeage with a second cysteine amino acid substitution in an Fc domain (e.g., an Fc domain of IgG1, IgG2, IgG3, IgG4) thereby forming a covalent complex with multivalent binding ability. The compositions provided herein exhibit highly specific binding with reduced or no endogenous Fc receptor binding activity thereby resulting in therapeutics that lack undesirable side effects.

This invention relates to an antibody composition, kit, and system for rapid screening of acute promyelocytic leukemia. The antibody composition comprises a first group of antibodies, a second group of antibodies, and a third group of antibodies. The first group of antibodies comprises antibodies against CD71, CD33, CD117, CD34, HLA-DR, CD19, CD10, CD7, and CD45. The second group of antibodies comprises antibodies against CD38, CD56, CD16, CD34, CD13, CD11b, CD64, CD15, and CD45. The third group of antibodies comprises antibodies against CD9, MPO, CD117, and CD45. Each of the antibodies is a monoclonal antibody labeled with a detection marker. The antibody composition contains a cell population targeting the CD117+CD33+ region, and includes three groups of antibodies that recognize acute promyelocytic leukemia, including CD33, CD34, CD64, CD13, CD9, and MPO. Using this antibody composition, acute promyelocytic leukemia can be detected quickly and easily with high sensitivity, specificity, and accuracy. It can accurately and rapidly identify patients with acute promyelocytic leukemia, enabling early diagnosis and treatment.

In some embodiments, compositions and methods relating to isolated artificial antigen presenting cells (aAPCs) are disclosed, including aAPCs comprising a U937 cell modified to express one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. Further provided are lipid nanoparticles (LNPs) conjugated to one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. In some embodiments, methods of expanding tumor infiltrating lymphocytes (TILs) with aAPCs or LNPs and methods of treating cancers using TILs after expansion with aAPCs or LNPs are also disclosed.

The disclosure describes T cells that express chimeric antigen receptors (CARs), as well as pharmaceutical compositions comprising T cells and methods of making and using such T cells. Particularly, this disclosure describes T cells expressing a CAR that binds to CD64, and methods of use in treating acute myeloid leukemia.